Metabotropic glutamate receptor 7 is a protein that in humans is encoded by the GRM7gene.[5][6][7]
Function
L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. Alternative splice variants of GRM8 have been described but their full-length nature has not been determined.[7]
Glutamate has lower affinity for mGluR7 than the other metabotropic glutamate receptors and it has been suggested that mGluR7 may have a regulatory role to dampen the effects of excessive glutamate levels.[8]
^Makoff A, Pilling C, Harrington K, Emson P (August 1996). "Human metabotropic glutamate receptor type 7: molecular cloning and mRNA distribution in the CNS". Brain Research. Molecular Brain Research. 40 (1): 165–170. doi:10.1016/0169-328X(96)00110-6. PMID8840028.
^ abPalucha A, Klak K, Branski P, van der Putten H, Flor PJ, Pilc A (November 2007). "Activation of the mGlu7 receptor elicits antidepressant-like effects in mice". Psychopharmacology. 194 (4): 555–562. doi:10.1007/s00213-007-0856-2. PMID17622518. S2CID22011436.
^Suzuki G, Tsukamoto N, Fushiki H, Kawagishi A, Nakamura M, Kurihara H, et al. (October 2007). "In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists". The Journal of Pharmacology and Experimental Therapeutics. 323 (1): 147–156. doi:10.1124/jpet.107.124701. PMID17609420. S2CID10402176.
^Kalinichev M, Rouillier M, Girard F, Royer-Urios I, Bournique B, Finn T, et al. (March 2013). "ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization". The Journal of Pharmacology and Experimental Therapeutics. 344 (3): 624–636. doi:10.1124/jpet.112.200915. PMID23257312. S2CID5774001.
Flor PJ, Van Der Putten H, Rüegg D, Lukic S, Leonhardt T, Bence M, et al. (February 1997). "A novel splice variant of a metabotropic glutamate receptor, human mGluR7b". Neuropharmacology. 36 (2): 153–159. doi:10.1016/S0028-3908(96)00176-1. PMID9144652. S2CID27492811.
Wu S, Wright RA, Rockey PK, Burgett SG, Arnold JS, Rosteck PR, et al. (January 1998). "Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells". Brain Research. Molecular Brain Research. 53 (1–2): 88–97. doi:10.1016/S0169-328X(97)00277-5. PMID9473604.
Barbon A, Ferraboli S, Barlati S (2000). "Assignment of the human metabotropic glutamate receptor gene GRM7 to chromosome 3p26.1→p25.2 by radiation hybrid mapping". Cytogenetics and Cell Genetics. 88 (3–4): 288. doi:10.1159/000015541. PMID10828612. S2CID202654909.
Bolonna AA, Kerwin RW, Munro J, Arranz MJ, Makoff AJ (January 2001). "Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia". Schizophrenia Research. 47 (1): 99–103. doi:10.1016/S0920-9964(99)00235-2. PMID11163549. S2CID40047571.
